The long-acting HIV treatment era is just beginning
Novel antibody-based regimen keeps HIV at bay for six months
Integrase inhibitor resistance after treatment failure more common in treatment-experienced people
Once-weekly combination of islatravir and lenacapavir safe and effective in 48-week study
Dolutegravir resistance very rare after a switch - even with detectable HIV
Most people on dolutegravir resuppress viral load after a detectable result
Lamivudine resistance mutation may persist for many years in some people with HIV
Retention in HIV care has declined since 'Treat All' guidelines introduced
Most liver disease in people with HIV in low and middle-income countries is caused by metabolic disorders
